Despite a downturn in M&A activity during the latter part of 2016, prospects are on the rise. In this article, we analyse what deals are on the table, coming to the table and those that are still in the kitchen waiting to be plated up!
A chunk of change
In general, one thing that can always be relied upon is the fact that there will be merger & acquisition (M&A) agreements in the pipeline or being completed upon at multiple points during the calendar year within the pharmaceutical industry. It is usually, as they say, ‘a dead cert’.